Search for dissertations about: "Green Fluorescent Proteins"
Showing result 1 - 5 of 47 swedish dissertations containing the words Green Fluorescent Proteins.
-
1. Metal Binding Tags - Characterisation, Use in Bioseparation and Applications of Green Fluorescent Fusion Proteins
Abstract : Most of the recombinant proteins produced nowadays are fused to affinity tags, in order to facilitate their purification through affinity chromato-graphy. Out the different tags available, poly-histidine tags are among the most commonly used and can help purification through immobilised metal ion affinity chromatography (IMAC). READ MORE
-
2. Hydrophobic Interactions in Bioseparation - Applications of Modified Green Fluorescent Protein
Abstract : This thesis describes interactions that are salt-promoted and mainly based on the hydrophobicity of proteins. A series of variants of the green fluorescent protein (GFP) was first constructed by site-directed mutagenesis. Several tags with various properties were then genetically fused to the N-terminus of GFP. READ MORE
-
3. Peptide-tagged proteins in aqueous two-phase systems
Abstract : This thesis deals with proteins containing peptide tags for improved partitioning in aqueous two-phase systems. Qualitatively the peptide-tagged protein partitioning could be predicted from peptide data, i.e. partitioning trends found for peptides were also found for the peptide-tagged proteins. READ MORE
-
4. Nanoparticle-based Capillary Electrochromatography - Separation of Small Molecules and Proteins
Abstract : The use of nanoparticle-based pseudostationary phases (PSPs) in capillary electrochromatography (CEC) for separation of small molecules and proteins is demonstrated. A continuous full filling approach is used where the nanoparticles are suspended in the electrolyte. READ MORE
-
5. Amyloid Beta – Biotherapy Target and Biotechnological Tool
Abstract : Alzheimer’s disease is a progressive neurodegenerative disease characterized primarily by memory impairment and cognitive decline. As of 2020, an estimated 50 million people suffer from Alzheimer’s disease or related dementia and no disease-modifying treatment options are yet approved for clinical practice. READ MORE